ES2543839T3 - Nuevas cepas del virus Chikungunya aisladas y purificadas y polinucleótidos y secuencias polipeptídicas, usos diagnósticos e inmunogénicos de las mismas - Google Patents

Nuevas cepas del virus Chikungunya aisladas y purificadas y polinucleótidos y secuencias polipeptídicas, usos diagnósticos e inmunogénicos de las mismas Download PDF

Info

Publication number
ES2543839T3
ES2543839T3 ES07734896.9T ES07734896T ES2543839T3 ES 2543839 T3 ES2543839 T3 ES 2543839T3 ES 07734896 T ES07734896 T ES 07734896T ES 2543839 T3 ES2543839 T3 ES 2543839T3
Authority
ES
Spain
Prior art keywords
virus
isolated
chik
fragment
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07734896.9T
Other languages
English (en)
Spanish (es)
Inventor
Philippe Despres
Anne-Claire Brehin
Valérie MARECHAL
Pierre Charneau
Philippe Souque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002538898A external-priority patent/CA2538898A1/fr
Application filed by Institut Pasteur filed Critical Institut Pasteur
Application granted granted Critical
Publication of ES2543839T3 publication Critical patent/ES2543839T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/181—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE or semliki forest virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
ES07734896.9T 2006-03-15 2007-03-15 Nuevas cepas del virus Chikungunya aisladas y purificadas y polinucleótidos y secuencias polipeptídicas, usos diagnósticos e inmunogénicos de las mismas Active ES2543839T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA002538898A CA2538898A1 (fr) 2006-03-15 2006-03-15 Nouvelles souches isolees et purifiees du virus chikungunya et sequences nucleotidiques et peptidiques, applications diagnostiques et immunogeniques
CA2538898 2006-03-15
CA2545597 2006-04-04
CA 2545597 CA2545597A1 (en) 2006-03-15 2006-04-04 Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
PCT/IB2007/001716 WO2007105111A2 (en) 2006-03-15 2007-03-15 Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof

Publications (1)

Publication Number Publication Date
ES2543839T3 true ES2543839T3 (es) 2015-08-24

Family

ID=38481184

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07734896.9T Active ES2543839T3 (es) 2006-03-15 2007-03-15 Nuevas cepas del virus Chikungunya aisladas y purificadas y polinucleótidos y secuencias polipeptídicas, usos diagnósticos e inmunogénicos de las mismas

Country Status (12)

Country Link
US (2) US20100055105A1 (enExample)
EP (2) EP2001900B1 (enExample)
JP (2) JP5923232B2 (enExample)
AU (1) AU2007226231B2 (enExample)
CA (2) CA2545597A1 (enExample)
DK (1) DK2001900T3 (enExample)
ES (1) ES2543839T3 (enExample)
HU (1) HUE025076T2 (enExample)
PL (1) PL2001900T3 (enExample)
PT (1) PT2001900E (enExample)
SI (1) SI2001900T1 (enExample)
WO (1) WO2007105111A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545597A1 (en) * 2006-03-15 2007-09-15 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
EP2073839B1 (en) * 2006-09-01 2016-10-19 Bharat Biotech International Limited A vaccine for chikungunya virus infection
CA2598966A1 (en) * 2007-09-07 2009-03-07 Institut Pasteur Anti-chikungunya monoclonal antibodies and uses thereof
FR2921064A1 (fr) * 2007-09-14 2009-03-20 Biomerieux Sa Oligonucleotides, utilisation, methode de detection et kit permettant de diagnostiquer la presence du gene e1 du virus du chikungunya
JP5744719B2 (ja) * 2008-04-04 2015-07-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法
EP2808405B1 (en) 2008-04-21 2018-06-06 Gen-Probe Incorporated Method for Detecting Chikungunya Virus
JP2012518431A (ja) * 2009-02-25 2012-08-16 ビッグテック プライベート リミテッド チクングニア検出用のプローブおよびプライマー
CN103476788A (zh) * 2010-12-10 2013-12-25 新加坡科技研究局 免疫原性屈曲病毒肽
WO2012131580A1 (en) * 2011-03-28 2012-10-04 Scms, Institute Of Bioscience And Biotechnology Research And Development Method of detecting chikungunya virus utilizing a recombinant el coat peptide antigen
EP2712871A1 (en) 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
US9701719B2 (en) 2012-09-27 2017-07-11 Research Development Foundation Attenuated Chikungunya virus
US11104916B2 (en) 2016-07-15 2021-08-31 Etubics Corporation Compositions and methods for alphavirus vaccination
TW202300515A (zh) 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
KR102757369B1 (ko) * 2017-09-21 2025-01-20 발네바 에스이 면역원성 치쿤구니야 바이러스 chikv-델타5nsp3을 포함하는 약제학적 조성물의 생산 방법
WO2020069054A1 (en) * 2018-09-27 2020-04-02 Texas Tech University System Stable cell line secreting chikungunya virus (chikv) virus like particles (vlp) for vaccines
PH12023550246A1 (en) * 2020-07-31 2024-06-24 Replicate Bioscience Inc Modified chikungunya viruses and sindbis viruses and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1922084A4 (en) * 2005-08-11 2011-01-12 Univ Texas INFECTIOUS CLONING OF CHICUNGUNYA VIRUS AND ITS USE
CA2545597A1 (en) * 2006-03-15 2007-09-15 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
EP2073839B1 (en) * 2006-09-01 2016-10-19 Bharat Biotech International Limited A vaccine for chikungunya virus infection

Also Published As

Publication number Publication date
JP2009529868A (ja) 2009-08-27
PL2001900T3 (pl) 2015-10-30
AU2007226231A1 (en) 2007-09-20
US20100055105A1 (en) 2010-03-04
PT2001900E (pt) 2015-09-15
JP5923232B2 (ja) 2016-05-24
CA2646520A1 (en) 2007-09-20
WO2007105111A3 (en) 2008-03-27
EP2001900B1 (en) 2015-04-29
JP2013126414A (ja) 2013-06-27
HUE025076T2 (en) 2016-02-29
SI2001900T1 (sl) 2015-09-30
EP2001900A2 (en) 2008-12-17
JP6104584B2 (ja) 2017-03-29
WO2007105111A2 (en) 2007-09-20
DK2001900T3 (en) 2015-07-27
EP2460822A2 (en) 2012-06-06
AU2007226231B2 (en) 2013-07-11
CA2646520C (en) 2018-05-15
US20150111197A1 (en) 2015-04-23
US9442114B2 (en) 2016-09-13
EP2460822A3 (en) 2012-09-26
CA2545597A1 (en) 2007-09-15

Similar Documents

Publication Publication Date Title
ES2543839T3 (es) Nuevas cepas del virus Chikungunya aisladas y purificadas y polinucleótidos y secuencias polipeptídicas, usos diagnósticos e inmunogénicos de las mismas
Schuffenecker et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak
Cecilia et al. Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants
ES2374131T3 (es) Flavivirus quiméricos avirulentos e inmunógenos.
Goncalvez et al. Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein
Deubel et al. Nucleotide sequence and deduced amino acid sequence of the nonstructural proteins of dengue type 2 virus, Jamaica genotype: comparative analysis of the full-length genome
Desprès et al. Differences between cell membrane fusion activities of two dengue type-1 isolates reflect modifications of viral structure
ES2226894T3 (es) Deteccion precoz de los flavivirus utilizando la glicoproteina ns1.
BRPI0913012B1 (pt) Quimera de ácido nucleico, métodos para detectar um anticorpo do vírus da dengue em uma amostra de um paciente, e para produzir partículas virais que expressam proteínas prm e e do vírus da dengue, uso de vírus codificado pela quimera e flavivírus ou partícula viral quiméricos
Wu et al. Japanese encephalitis virus antigenic variants with characteristic differences in neutralization resistance and mouse virulence
EP2959915A1 (en) A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
CN113637086A (zh) 用于疫苗中的登革热病毒嵌合式构建物的组合物及方法
Seif et al. Finer mapping of neutralizing epitope (s) on the C-terminal of Japanese encephalitis virus E-protein expressed in recombinant Escherichia coli system
CN107207619A (zh) 用于疫苗及诊断开发的重组登革病毒的方法及组合物
CN113248608B (zh) 一种基孔肯雅病毒e2蛋白兔单克隆抗体及其用途
CA2579507C (en) Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
US7482017B2 (en) Flavivirus variants having phenotypic variation and immunogenic compositions thereof
Vlaycheva et al. Neuroblastoma cell-adapted yellow fever virus: mutagenesis of the E protein locus involved in persistent infection and its effects on virus penetration and spread
ES2252918T3 (es) Cepa fiv-141 del virus de la inmunodeficiencia felina y sus usos.
Shiu et al. Louping ill virus envelope protein expressed by recombinant baculovirus and vaccinia virus fails to stimulate protective immunity
CN113248607A (zh) 一种基孔肯雅病毒e2蛋白兔单克隆抗体及其在开发治疗性抗体中的用途
Botha Molecular characterization of South African lineage II West Nile virus isolates and development of a diagnostic assay
Messera et al. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity
Nickells Molecular basis of yellow fever virus neurovirulence
de Alwis Dissecting the Human Antibody Response to Dengue Virus